Back to Search Start Over

Apamin structure and pharmacology revisited.

Authors :
Kuzmenkov AI
Peigneur S
Nasburg JA
Mineev KS
Nikolaev MV
Pinheiro-Junior EL
Arseniev AS
Wulff H
Tytgat J
Vassilevski AA
Source :
Frontiers in pharmacology [Front Pharmacol] 2022 Sep 16; Vol. 13, pp. 977440. Date of Electronic Publication: 2022 Sep 16 (Print Publication: 2022).
Publication Year :
2022

Abstract

Apamin is often cited as one of the few substances selectively acting on small-conductance Ca <superscript>2+</superscript> -activated potassium channels (K <subscript>Ca</subscript> 2). However, published pharmacological and structural data remain controversial. Here, we investigated the molecular pharmacology of apamin by two-electrode voltage-clamp in Xenopus laevis oocytes and patch-clamp in HEK293, COS7, and CHO cells expressing the studied ion channels, as well as in isolated rat brain neurons. The microtitre broth dilution method was used for antimicrobial activity screening. The spatial structure of apamin in aqueous solution was determined by NMR spectroscopy. We tested apamin against 42 ion channels (K <subscript>Ca</subscript> , K <subscript>V</subscript> , Na <subscript>V</subscript> , nAChR, ASIC, and others) and confirmed its unique selectivity to K <subscript>Ca</subscript> 2 channels. No antimicrobial activity was detected for apamin against Gram-positive or Gram-negative bacteria. The NMR solution structure of apamin was deposited in the Protein Data Bank. The results presented here demonstrate that apamin is a selective nanomolar or even subnanomolar-affinity K <subscript>Ca</subscript> 2 inhibitor with no significant effects on other molecular targets. The spatial structure as well as ample functional data provided here support the use of apamin as a K <subscript>Ca</subscript> 2-selective pharmacological tool and as a template for drug design.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Kuzmenkov, Peigneur, Nasburg, Mineev, Nikolaev, Pinheiro-Junior, Arseniev, Wulff, Tytgat and Vassilevski.)

Details

Language :
English
ISSN :
1663-9812
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in pharmacology
Publication Type :
Academic Journal
Accession number :
36188602
Full Text :
https://doi.org/10.3389/fphar.2022.977440